English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 26 January 2021, 11:58 JST
Share:
    

Source: Eisai
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fifth Time

TOKYO, Jan 26, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that it has been listed in the 2021 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai's fifth inclusion on the list. Ranked 16rd, Eisai was the highest ranking company among global pharmaceutical companies. Also, Eisai became the highest ranking Japanese company among the five Japanese companies listed in the Global 100.

The Global 100 evaluates the sustainability of approximately 8,100 of the world's major corporations based on various corporate initiatives in areas such as ESG (environment, society and governance). Since 2005, those companies ranking among the top 100 in the world have been announced each year at the World Economic Forum in Davos week. The Global 100 is based on up to 24 key performance indicators covering clean revenue, financial management, supplier performance, employee management and resource management, with the evaluations carried out based on data publicly disclosed in financial filings, integrated reports, or through other such channels. Eisai received high evaluation particularly on clean revenue and investment*, as well as employee safety and stability.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Based on this corporate philosophy, Eisai is striving to sustainably enhance corporate value by strengthening its ESG initiatives and increasing non-financial value.

* Sales revenue, R&D cost and investment for products such as medicines which are under equitable pricing strategies and included in the WHO Essentials Medicines Lists or used to treat any of in scope diseases, conditions and pathogens defined by the ATM Index Foundation.

Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Monday, 2 March 2026, 9:49 JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
2026年3月2日 8時45分 JST
エーザイとMerck & Co.,Inc.、「レンビマ(R)」(レンバチニブ)と「ウェリレグ(R)」(ベルズチファン)の併用療法が治療歴のある進行腎細胞がんにおいて、カボザンチニブと比較して、疾患進行または死亡のリスクを30%低減
2026年2月16日 15時00分 JST
エーザイ、新規オレキシン受容体作動薬 E2086 が日本において、ナルコレプシーを対象として、厚生労働省より希少疾病用医薬品に指定
Monday, 16 February 2026, 14:03 JST
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
Tuesday, 10 February 2026, 13:34 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
More news >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575